RxDoctor Payments Data

James Mok, MD

Orthopaedic Surgery of the Spine · Stanford, CANPI 1831271436

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $232,552 of the $371,476 with a category attached, or 62.6%. Mirus, LLC accounts for 90.4% of it on its own, with 21 other manufacturers making up the rest.

$371,476in general payments, 2019–2025

Across 165 payments — averaging $2251.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirus, LLC$336K
  • Amplify Surgical, Inc.$13K
  • Medynus Inc$7K
  • Si-bone, Inc.$6K
  • Globus Medical$3K
  • Baxter Healthcare$2K
  • plus $4K from 16 others
$10,000in research payments, 2019–2025

Across 3 payments — averaging $3333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Additive Implants, Inc.$10K

What the payments were for

  • Royalty or licence$122,38133%
  • Consulting fees$232,55263%
  • Travel & lodging$10,4653%
  • Food & beverage$5,5011%
  • Education$5770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$371,476 in reported general payments places this provider in the 80th percentile of 288 orthopaedic surgery of the spine providers in California.

See all orthopaedic surgery of the spine providers in California

Medicare billing

Part B allowed, 2024
$380,101
Medicare patients
408
Services billed
1,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin29$502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$300
Tizanidine Hcl18$107
Meloxicam15$105
Methylprednisolone17$94

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →